HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Juweid, M. Articles by Goldenberg, D. M. Search for Related Content PubMed PubMed Citation Articles by Juweid, M. Articles by Goldenberg, D. M.

Radioimmunotherapy of Medullary Thyroid Cancer with Iodine-131-Labeled Anti-CEA Antibodies

Garden State Cancer Center, Center for Molecular Medicine and Immunology, Newark, New Jersey
St. Joseph's Hospital and Medical Center, Paterson, New Jersey

Correspondence: For correspondence or reprints contact: David M. Goldenberg, MD, Garden State Cancer Center, Center for Molecular Medicine and Immunology, 1 Bruce St., Newark, NJ 07103.

ABSTRACT

This study evaluates the pharmacokinetics, dosimetry, toxicity and therapeutic potential of radiolabeled NP-4 and MN-14 anti-CEA antibodies in medullary thyroid cancer (MTC). Methods: Eighteen patients with advanced MTC entered exploratory clinical studies with therapeutic doses of ¹³¹I-labeled NP-4 and MN-14 murine monoclonal antibodies (MAbs) reactive with carcinoembryonic antigen (CEA). Doses administered ranged from 46 mCi for ¹³¹I-MN-14 IgG to 195 mCi for ¹³¹I-MN-14 F(ab)₂ in patients negative for human anti-mouse antibodies (HAMA). Results: The radioconjugate blood half-life (T1/2) for the whole IgG was 42.5 ± 5.0 hr compared to 18.8 ± 4.1 hr for the bivalent fragments. Tumor doses of 17.5 ± 11.0 and 11.4 ± 6.3 cGy/mCi were estimated for ¹³¹I-MN-14 IgG and F(ab)₂, respectively. Tumor/red marrow dose ratios exceeded 3:1 for most lesions. Red marrow doses of up to 350 cGy generally could be delivered with < grade 4 toxicity. Seven of 14 evaluable patients showed evidence of anti-tumor effects lasting up to 26 months, based on physical exam, tumor markers or computed tomography. Conclusion: This study demonstrates that anti-CEA MAbs may be suitable for radioimmunotherapy of metastatic or recurrent MTC.

Key Words: radioimmunotherapy • medullary thyroid cancer • carcinoembryonic antigen • monoclonal antibodies

This article has been cited by other articles:

				A. Oudoux, P.-Y. Salaun, C. Bournaud, L. Campion, C. Ansquer, C. Rousseau, S. Bardet, F. Borson-Chazot, J.-P. Vuillez, A. Murat, et al. Sensitivity and Prognostic Value of Positron Emission Tomography with F-18-Fluorodeoxyglucose and Sensitivity of Immunoscintigraphy in Patients with Medullary Thyroid Carcinoma Treated with Anticarcinoembryonic Antigen-Targeted Radioimmunotherapy J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4590 - 4597. [Abstract] [Full Text] [PDF]

				V. Johanson, H. Ahlman, P. Bernhardt, S. Jansson, L. Kolby, F. Persson, G. Stenman, C. Sward, B. Wangberg, M. Stridsberg, et al. A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis Endocr. Relat. Cancer, June 1, 2007; 14(2): 433 - 444. [Abstract] [Full Text] [PDF]

				F. Kraeber-Bodere, C. Sai-Maurel, L. Campion, A. Faivre-Chauvet, E. Mirallie, M. Cherel, S. Supiot, J. Barbet, J.-F. Chatal, and P. Thedrez Enhanced Antitumor Activity of Combined Pretargeted Radioimmunotherapy and Paclitaxel in Medullary Thyroid Cancer Xenograft Mol. Cancer Ther., February 1, 2002; 1(4): 267 - 274. [Abstract] [Full Text] [PDF]

				J. Y. C. Wong, D. Z. Chu, D. M. Yamauchi, L. E. Williams, A. Liu, S. Wilczynski, A. M. Wu, J. E. Shively, J. H. Doroshow, and A. A. Raubitschek A Phase I Radioimmunotherapy Trial Evaluating 90Yttrium-labeled Anti-Carcinoembryonic Antigen (CEA) Chimeric T84.66 in Patients with Metastatic CEA-producing Malignancies Clin. Cancer Res., October 1, 2000; 6(10): 3855 - 3863. [Abstract] [Full Text]

				C. de Labriolle-Vaylet, P. Cattan, E. Sarfati, M. Wioland, C. Billotey, C. Brochériou, E. Rouvier, A. de Roquancourt, W. Rostène, S. Askienazy, et al. Successful Surgical Removal of Occult Metastases of Medullary Thyroid Carcinoma Recurrences with the Help of Immunoscintigraphy and Radioimmunoguided Surgery Clin. Cancer Res., February 1, 2000; 6(2): 363 - 371. [Abstract] [Full Text]

				Q. Wang, S. Takashima, H. Fukuda, F. Takayama, S. Kobayashi, and S. Sone Detection of Medullary Thyroid Carcinoma and Regional Lymph Node Metastases by Magnetic Resonance Imaging Arch Otolaryngol Head Neck Surg, August 1, 1999; 125(8): 842 - 848. [Abstract] [Full Text] [PDF]